Table 3. Risk factors for ureteroenteric stricture development.
| Variable | Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age at surgery (continuous) | 1.01 | 0.99–1.02 | 0.35 | ||||
| Gender (ref. female) | 1.07 | 0.73–1.58 | 0.73 | ||||
| BMI (continuous) | 1.06 | 1.03–1.09 | <0.0001 | 1.05 | 1.02–1.09 | 0.038 | |
| Preoperative GFR (continuous) | 1.00 | 0.99–1.01 | 0.95 | ||||
| ECOG (ref. ≤1) | 0.47 | 0.19–1.16 | 0.12 | ||||
| Chemotherapy | 1.17 | 0.84–1.62 | 0.35 | ||||
| Radiation therapy | 1.25 | 0.80–1.87 | 0.35 | ||||
| Smoking | 0.87 | 0.60–1.24 | 0.62 | ||||
| BCG treatment | 1.02 | 0.71–1.48 | 0.91 | ||||
| Preoperative hydronephrosis | 0.67 | 0.47–0.97 | 0.03 | 0.79 | 0.45–1.39 | 0.41 | |
| Operative time, min. (continuous) | 1.01 | 1.00–1.01 | 0.01 | 1.01 | 0.96–1.05 | 0.83 | |
| EBL, cc (continuous) | 1.00 | 1.00–1.00 | 0.21 | ||||
| Pathologic stage (pT3/4 vs. ≤T2) | 0.71 | 0.50–0.99 | 0.06 | 0.95 | 0.54–1.66 | 0.83 | |
| ≤30–day urine leak | 1.56 | 0.82–2.97 | 0.18 | ||||
| ≤30–day UTI | 2.18 | 1.09–4.35 | 0.03 | 1.64 | 0.78–3.46 | 0.19 | |
| ≤30–day abscess | 0.21 | 0.03–1.49 | 0.12 | ||||
| Max Clavien complication (grade ≥3 vs. <3) | 2.44 | 1.71–3.50 | <0.0001 | 2.07 | 1.18–3.63 | 0.01 | |
OR, odds ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; BCG, Bacillus Calmette-Guerin; EBL, estimated blood loss; GFR, glomerular filtration rate; UTI, urinary tract infection.